Orchid Cellmark Reports First Quarter 2008 Financi...(iabilities and Stockholders' Equity: ...),Health
Navigation Links
Orchid Cellmark Reports First Quarter 2008 Financial Results
Date:5/8/2008
iabilities and Stockholders' Equity:
Current liabilities
Accounts payable $1,644 $2,027
Accrued expenses and other current liabilities 5,036 4,611
Income taxes payable 178 543
Short-term debt and current portion of
long-term debt 400 428
Deferred revenue 992 964
Total current liabilities 8,250 8,573
Other liabilities 604 1,123
Total liabilities 8,854 9,696
Total stockholders' equity 50,395 52,433
Total liabilities and stockholders' equity $59,249 $62,129
'/>"/>
| SOURCE Orchid Cellmark Inc. Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. Orchid Cellmark to Open a New Forensic Facility in the United Kingdom to Meet Increasing Demand for Its Services
2. Orchid Cellmark Reports Fourth Quarter and Full Year 2007 Financial Results
3. Orchid Cellmark to Announce Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
4. Orchid Cellmark Appoints William J. Thomas Vice President and General Counsel
5. Orchid Cellmark Reports Third Quarter 2007 Financial Results
6. Neurotechnology Industry Reports Record Global Growth of $130.5 Billion in 2007
7. Micromet, Inc. Reports First Quarter 2008 Financial Results
8. Labopharm Reports Results for First Quarter Fiscal 2008
9. Caliper Life Sciences Reports First Quarter 2008 Results
10. US Oncology Reports First Quarter 2008 Results
11. The Ensign Group, Inc. Reports First Quarter 2008 Earnings
Post Your Comments:
(Date:11/22/2009)...ause donated cells to attack recipient,s tissue, s...Day News) -- Researchers are reporting that a gene... that someone who,s had a bone-marrow transplant w...t disease. , The immune system-related complic...the variation and the donor does not. , When t...
(Date:11/22/2009)...NGTON, Nov. 21 Congress...ment upon the United States Senate,s vote tonight ...islation: ,, "Senators Arlen Specter and Bob Ca...ennsylvanians for casting stand-up, critical votes... historic Affordable Health Care Reform legislatio...
(Date:11/21/2009)...SHINGTON, Nov. 21 A reg...e onchocerciasis (river blindness) in the Americas...isease in recent years, as evidenced by a 31% decr...rug administration in six endemic countries. Resu... of the American Society of Tropical Medicine and ...
(Date:11/21/2009)... HAPPYneuron,s most popular and addictiv... and iPod Touch. , Mounta...on,s most popular and addictive game, SplitWords, ...it Words is designed to help banish that ,tip of t...iPhone brain game challenges the brain by encoura...
(Date:11/20/2009)...NCETON, NJ, Nov. 20 /PRNewswire-FirstCall/ - NUCRY...ecial Meeting of Shareholders will be held on Mond...is to consider approval of two special resolutions...uthorize the sale of all or substantially all of t...rovided for in the asset purchase agreement dated ...
Breaking Medicine News(10 mins):Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 2Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 3Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 4Health News:HAPPYneuron releases iPhone Brain Game 2Health News:HAPPYneuron releases iPhone Brain Game 3Health News:NUCRYST Announces Special Meeting of Shareholders 2Health News:NUCRYST Announces Special Meeting of Shareholders 3[0] Missing Gene Tied to Bone Marrow Transplant Problems[0] Congressman Fattah: Thanks to Specter, Casey for a Major Step Along History's Path[0] River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries[0] HAPPYneuron releases iPhone Brain Game [0] NUCRYST Announces Special Meeting of Shareholders
...2 Perot Systems,Corporation (NYSE: PER ) and Sur...eement in which Perot Systems will implement advan...r business growth. Through this,agreement, Perot S...ountry. Perot Systems, services will include:,stra...
...a Motor Co., Ltd. will showcase an,experimental mo... walking,for the elderly and other people with wea... on Barrier Free Equipments & Rehabilitation for,t...w.newscom.com/cgi-bin/prnh/20080422/LATU095A ), D...
... 2008 Help is on the way for patients who have un...om chronic pain in their backs and legs, thanks to...pain management specialists. , Called a hybrid ...pheral nerve field stimulation (PNFS). This lates...
...ity, may abolish post-operative arthritic knee pai...ective surgery to repair a common sports-related k...nt), is now available in Michigan., "This innovat...o a degree never seen before with traditional ACL,...
...ints to a new strategy for preventing or possibly ...organ and tissue damage researchers at the Unive...have determined that a molecule called Epac (Excha...ine edition of the Proceedings of the National Aca...
...OrbusNeich,s Genous Bio-engineered,R stent will be...sty Summit,TCT 2008 Asia Pacific., The symposium,...on,Center of Sheraton Grande Walkerhill Seoul Hote...al Progenitor Cell Capture Technology and Beyond" ...
Other Medicine News:Health News:Perot Systems and Surgical Care Affiliates Sign Five-Year Agreement to Implement Advanced Technology Solutions 2Health News:Perot Systems and Surgical Care Affiliates Sign Five-Year Agreement to Implement Advanced Technology Solutions 3Health News:Honda to Showcase Experimental Walking Assist Device 2Health News:Mix of 2 pain-relief procedures can end chronic back and leg pain without drugs 2Health News:Mix of 2 pain-relief procedures can end chronic back and leg pain without drugs 3Health News:Two Michigan Orthopedic Surgeons Pioneer Innovative ACL Surgery with New Benefits for Athletes, Weekend Warriors 2Health News:Two Michigan Orthopedic Surgeons Pioneer Innovative ACL Surgery with New Benefits for Athletes, Weekend Warriors 3Health News:Scientists identify novel way to prevent cardiac fibrosis 2Health News:Symposium at Angioplasty Summit TCT Asia Pacific 2008 Features OrbusNeich's Genous(TM) Bio-engineered R stent(TM) 2Perot Systems and Surgical Care Affiliates Sign Five-Year Agreement to Implement Advanced Technology SolutionsHonda to Showcase Experimental Walking Assist DeviceMix of 2 pain-relief procedures can end chronic back and leg pain without drugsTwo Michigan Orthopedic Surgeons Pioneer Innovative ACL Surgery with New Benefits for Athletes, Weekend WarriorsScientists identify novel way to prevent cardiac fibrosisSymposium at Angioplasty Summit TCT Asia Pacific 2008 Features OrbusNeich's Genous(TM) Bio-engineered R stent(TM)
(Date:11/20/2009)... , PLYMOUTH MEETING, Pa., Nov. 20 /PRNewswir... Times article that questions why currently avail...e cancers are being ignored, ECRI Institute, an in...admap to the evidence on Finasteride for Preventi...The November 13, 2009, New York Times article, "...
(Date:11/20/2009)..., MEMPHIS, Tenn., Nov. 20 /PRNewswire-FirstCa...dics Division is pleased to announce the signing o...d States Department of Defense that may lead to th...to revolutionize the treatment of the limbs of sol... year, the Defense Advanced Research Projects Agen...
(Date:11/19/2009)... , ARDEE, Ireland, Nov. 19 War...the pricing of its previously announced secondary ... price to the public of $22.25 per share. The sel...in Capital Partners, DLJ Merchant Banking, J.P. Mo... H. Lee Partners, L.P., certain other institutiona...
Breaking Medicine Technology:ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 2ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 3Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 2Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 3Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 4Warner Chilcott Prices Secondary Equity Offering 2Warner Chilcott Prices Secondary Equity Offering 3Warner Chilcott Prices Secondary Equity Offering 4CEM Wins Presidential Green Chemistry Challenge Award for the Sprint Rapid Protein Analyzer 12724 1CEM Wins Presidential Green Chemistry Challenge Award for the Sprint Rapid Protein Analyzer 12724 2KV Pharmaceutical Receives Letter From NYSE Regarding Delayed Filing of Its 2009 Annual Report on Form 10 K 49600 1KV Pharmaceutical Receives Letter From NYSE Regarding Delayed Filing of Its 2009 Annual Report on Form 10 K 49600 2KV Pharmaceutical Receives Letter From NYSE Regarding Delayed Filing of Its 2009 Annual Report on Form 10 K 49600 3KV Pharmaceutical Receives Letter From NYSE Regarding Delayed Filing of Its 2009 Annual Report on Form 10 K 49600 4KV Pharmaceutical Receives Letter From NYSE Regarding Delayed Filing of Its 2009 Annual Report on Form 10 K 49600 5KV Pharmaceutical Receives Letter From NYSE Regarding Delayed Filing of Its 2009 Annual Report on Form 10 K 49600 6 New Strategy Eyed for AIDS Treatment 49598 1 New Strategy Eyed for AIDS Treatment 49598 2[0] ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists[0] Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries[0] Warner Chilcott Prices Secondary Equity Offering
...itor, and R7128, nucleoside polymerase inhibitor, ...n patients with hepatitis C - , , NUTLEY, N.J., ...oche, InterMune, Inc. (Nasdaq: ITMN ) and Pharma...esults from their innovative, interferon-free regi...herapy for the treatment of patients chronically i...
...rmed to date will be presented during the Internat...nnual Meeting in Paris, France on April 24, 2009 ...d as an in vitro assessment of cell-mediated imm...erous clinical investigations have contributed to ...g recipients of solid organ transplants. , , (Lo...
Other Medicine Technology:Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 2Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 3Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 4Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 5Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 6Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 7Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 8Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 9Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 10Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 11An Independent Study Reports on the Utility of ImmuKnow(R), the Cylex(TM) Immune Cell Function Assay, for Monitoring Heart Transplant Recipients 2...cientific principles supporting the effectiveness ...sed upon extensive clinical studies. As a woman ne...vel increases, thereby, elevating the salt in her ...ed to dry, crystalization occurs. The closer a wom...
Gastroccult Gastric Occult and pH Test
SureStep™ FSH Menopause Test (mid-stream)
FSH Home Menopause Test Midstream (Urine)
Medicine Products:| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |